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ABSTRACT 
Type 1 interferons (IFN-α /β ) are key mediators of innate antiviral responses but have 
little effect on established replication of dengue viruses, which are mosquito-borne 
flaviviruses of immense global health importance. Understanding how the IFN system 
is inhibited in dengue virus-infected cells would provide critical insight into disease 
pathogenesis. In a recent study analyzing the ability of individual dengue virus-
encoded proteins to antagonize the IFN response, non-structural (NS) protein 4B, and 
possibly NS2A and NS4A, were identified as candidate IFN antagonists. In monkey 
cells, NS4B appeared to inhibit both IFN-α /β  and IFN-γ  signal transduction 
pathways, which are distinct but overlapping (Munoz-Jordan, J. L., G. G. Sanchez-
Burgos, M. Laurent-Rolle, and A. Garcia-Sastre. 2003. Proc Natl Acad Sci U S A 
100:14333-8). Here we examine the effects of dengue on the human IFN system using 
cell lines that are stably transfected with self-replicating subgenomic dengue RNA 
(replicons) and express all the dengue non-structural proteins together. We show that 
in replicon-containing cells dengue RNA replication and replication of 
encephalomyocarditis virus, an IFN-sensitive virus, are resistant to the antiviral 
effects of IFN-α . The presence of dengue replicons reduces global IFN-α -stimulated 
gene expression, and specifically inhibits IFN-α , but not IFN-γ , signal transduction. 
In cells containing replicons, or infected with dengue virus, we found reduced levels 
of signal transducer and activator of transcription (STAT) 2, which is a key 
component of IFN-α  but not IFN-γ  signaling. Collectively, these data show that 
dengue virus is capable of subverting the human IFN response by down-regulating 
STAT2 expression. 
  3
INTRODUCTION 
Dengue viruses are mosquito-borne flaviviruses of immense global public health 
importance, causing tens of millions of human infections worldwide each year (11).  
Intensity of viral replication in the first days of infection determines clinical outcome, 
which ranges from benign febrile illness to life-threatening disease (dengue 
hemorrhagic fever) (39). During this critical early phase, prior to full recruitment of 
antigen-specific defenses, innate cellular antiviral mechanisms mediated by IFN-α /β  
are potentially the most important pathways of host defense limiting viral replication. 
Virus infection classically induces secretion of IFN-α /β , which bind to cell-surface 
IFN alpha receptors (IFNAR, comprising IFNAR1 and IFNAR2 subunits) on infected 
and nearby cells. Binding of IFN-α /β  to IFNAR leads to activation of Jak1 and Tyk2 
kinases via tyrosine phosphorylation (4). In turn, STAT2 and then STAT1 are 
phosphorylated and form heterodimers, which then associate with p48/IRF-9 to form 
ISGF3 complexes (12). ISGF3 complexes translocate to the nucleus and initiate 
transcription of interferon-stimulated genes (ISGs) by binding interferon-stimulated 
response elements (ISREs), leading to transcriptional up-regulation of hundreds of 
cellular genes and induction of an antiviral state (35).  
 
Experimental evidence suggests that the IFN system may play an important role in 
limiting dengue virus replication, since knockout mice that lack type 1 IFN receptors 
develop severe infection after challenge with dengue virus (15, 34). Also, pre-
treatment of cultured cells with IFN-α/β  dramatically reduces dengue virus 
replication (5, 6). This occurs primarily through inhibition of translation of input 
strand dengue RNA, by an unknown mechanism (5). In contrast, IFN-α/β  has little 
effect on dengue replication after viral replication has been established (5, 6),  4
suggesting that the IFN system can not fully engage in dengue-infected cells. In 
keeping with this observation, dengue virus can achieve high titres (<10
9 infectious 
doses per ml) in humans despite induction of high levels of circulating IFN-α  (21, 36, 
39). It seems likely therefore that dengue virus has evolved mechanisms to counter the 
IFN response, although not absolutely, which is a characteristic that may be shared by 
many pathogenic viruses (9, 42). 
 
Muñoz-Jordan and colleagues recently published an in vitro study that analyzed the 
ability of individual dengue proteins to block the IFN system, and concluded that 
NS4B, and possibly NS2A and NS4A, may act as IFN-signaling inhibitors (25). They 
showed that NS4B, and dengue virus infection, blocked signal transduction in 
response to both IFN-β  and IFN-γ  in a monkey kidney cell line, suggesting that the 
target for NS4B-mediated inhibition of IFN signaling may be a component (possibly 
phosphorylated STAT1 (STAT1-P)) that is common to these distinct but overlapping 
signal transduction pathways (25). We adopted a complementary experimental 
approach specifically aimed at studying the effect of dengue virus replication 
downstream of translation of input strand RNA on the human IFN system. We first 
established human cell lines that continuously express self-replicating subgenomic 
dengue RNA (replicons). Flavivirus replicons express all the viral non-structural 
proteins together in a way that mimics expression during authentic viral infection, and 
have proved powerful tools for studying the functional roles of non-structural proteins 
in RNA and virus replication (16-18, 24). We show here that the presence of dengue 
replicons in human cell lines inhibits the antiviral effect of IFN-α  by blocking early 
events in IFN-α  signal transduction, resulting in reduced levels of STAT1-P. In 
contrast, STAT1-P levels in replicon-containing cells are increased rather than  5
reduced in response to IFN-γ . We show that steady-state levels of STAT2 are reduced 
in cells containing dengue replicons, which is consistent with the observed responses 
to IFN-α  and IFN-γ . Reduced STAT2 levels are also found in cells infected with 
dengue virus, suggesting that dengue virus is capable of subverting the human IFN 
response by down-regulating STAT2 expression.  6
MATERIALS AND METHODS 
Cell lines stably expressing dengue replicons. A series of cell lines that 
continuously express dengue replicons have been established in our laboratory 
(manuscript in preparation). In this study, K562 (human chronic myeloid leukemia) 
and THP-1 (human monocytic) cell lines stably expressing the dengue replicon 
∆ CprME-PAC2A were used (designated K562.∆ CprME-PAC2A and THP-
1.∆ CprME-PAC2A respectively). The plasmid pDEN∆ CprME-PAC2A was used for 
in vitro transcription of ∆ CprME-PAC2A replicon RNA. pDEN∆ CprME-PAC2A was 
derived from pDVWS601 (29), which contains a genomic length dengue virus type 2 
(New Guinea C strain) cDNA clone, by the introduction of a large in-frame deletion 
in the structural region, retaining only the first 27 codons of the C gene and the last 24 
codons of the E gene. In addition, pDEN∆ CprME-PAC2A contains an antibiotic 
selection cassette encoding puromycin N-acetyl transferase (PAC) followed by an 
artificial protein “cleavage” site (foot-and-mouth disease virus protein 2A) in place of 
the deleted structural genes (Fig. 1). Cells stably expressing dengue replicon RNA 
were generated by transfection with ∆ CprME-PAC2A RNA and then propagation in 
RPMI containing 10% FBS and 3 µg/ml puromycin (Sigma). Cells were removed 
from puromycin selection and checked for replicon expression before use by indirect 
immunofluorescence for dengue NS1 protein, using a specific monoclonal antibody 
(5H5.4, (7)). K562 and THP-1 cells without replicons were continuously maintained 
in the same medium without puromycin. 
 
“Cured” K562 cell line. K562 cells that were stably expressing ∆ CprME-PAC2A 
were removed from puromycin selection and passaged continuously in RPMI 
containing 10% FBS and 500 µg/ml glycyrrhizic acid (Fluka Chemicals), which has  7
activity against RNA viruses through an unknown mechanism (3). At intervals, cells 
were checked for replicon expression by indirect immunofluorescence for dengue 
NS1 protein and RT-PCR for dengue RNA (see below). Once the cell line had been 
“cured” of the replicon, it was subsequently grown in RPMI containing 10% FBS, 
without glycyrrhizic acid, and checked for the continued absence of replicons as 
before. 
 
Analysis of dengue RNA levels and NS1 expression. K562.∆ CprME-PAC2A cells 
were grown in the presence of 0, 10, 100, 1000 or 10000 IU/ml IFN-α 2a (Roferon-A, 
Roche) for 24 hours, and then total cellular RNA was extracted in Trizol (Invitrogen). 
Extracted RNA was treated with RQ1 RNase-free DNase (Promega) and reverse 
transcribed with M-MLV reverse transcriptase (Promega) using random decamer 
primers. The PCR reaction was performed and analyzed on the Rotorgene (Corbett 
Research) using custom primers and a fluorescent probe specific for dengue NS1 
(forward 5’CTGAAGTGTGGCAGTGGGATT, reverse 5’CTTCAAAGCTAGC 
TTCAGCTATCCA and probe 5’CACAGACAACGTGCACACATGGACAGA). The 
housekeeping gene GAPDH was analysed in the same samples using specific primers 
(forward 5’ACAGTCCATGCCATCACTGCC, reverse 5’GCCTGCTTCACCACCTT 
CTTG) and QuantiTect SYBR green (Qiagen). In parallel experiments, 
K562.∆ CprME-PAC2A cells were grown in the presence of 100 IU/ml IFN-α 2a and 
cell-associated and secreted dengue NS1 protein were analysed by immunoblotting 
and ELISA, respectively, as previously described (14, 44). 
 
EMCV trans rescue assay. K562 cells that did and did not contain dengue replicons 
were grown in RPMI containing 10% FBS with 0, 10 and 100 IU/ml IFN-α 2a for 24  8
hours. Cells were washed in RPMI and 1 x 10
6 cells were then infected with 5 x 10
5 
pfu of encephalomyocarditis virus (EMCV) in RPMI containing 2% FBS for 1 hour. 
Cells were washed and then cultured for a further 24 hours in RPMI + 10% FBS. 
Culture supernatants were then harvested, and serial dilutions were plated on to 
confluent A549 cells in a 96-well plate for 1 hour before replacing the inoculum with 
RPMI containing 10% FBS. After a further 24 hours, the A549 cells were fixed and 
stained with methyl violet, and the optical density in each well was read at 570 nm in 
an automated plate reader (27). 
 
MxA and PKR gene expression. K562 and K562.∆ CprME-PAC2A cells were 
grown in the presence or absence of 100 IU/ml IFN-α 2a for 6 and 24 hours. RNA 
extraction and reverse transcription were performed as described above. PCR 
reactions were performed and analyzed on the Rotorgene using SYBR green as 
before, using specific primers for the MxA gene (forward 
5’AACAACCTGTGCAGCCAGTA, reverse 5’AAGGGCAACTCCTGAGAGTG) or 
PKR gene (forward 5’TCTCTGGCGGTCTTCAGAAT, reverse 5’ACTCCCTGCTT 
CTGACGGTA). The housekeeping gene GAPDH was analysed in the same samples 
as described above. 
 
ISG expression profiling: macroarray analysis. K562 and K562.∆ CprME-PAC2A 
cells (2 x10
7 per reaction) were treated with 100 IU/ml IFN-α 2a for 24 hours before 
extracting total cellular RNA with Trizol. Radiolabelled cDNA was generated from 
20 µg total RNA by reverse transcription with Superscript II (Gibco) in the presence 
of 
32P-dCTP. Residual RNA was hydrolysed by alkaline treatment at 70 °C for 20 
min., and the cDNA was purified using G-50 columns (Amersham Pharmacia).  9
Before hybridisation to the macroarrays the labelled cDNA was mixed with 50 µg 
COT-DNA (Gibco) and 10 µg Poly-A DNA (Sigma), denatured at 95°C for 5 min., 
and hybridised for 1 hour to minimise non-specific binding. Preparation of the 
macroarrays (representing 150 genes, including many known to be stimulated by 
interferon), hybridisation of the radioactive cDNAs and scanning and analysis of the 
macroarrays were carried out as described previously (33). 
 
Immunoblotting. K562 cells (2.5 x 10
5 per reaction) that did and did not contain 
replicon were stimulated with 100 IU/ml IFN-α 2a or IFN-γ  (R&D Systems) for 30 
min. Unstimulated cells were included for comparison. Cells were harvested and 
lysed in 250 µl SDS loading buffer (0.0625 M phosphate, pH 7.0, 10% glycerol, 2% 
SDS, 0.001% bromophenol blue) pre-warmed to 60 °C. Ten µl of each sample was 
separated by SDS-PAGE electrophoresis, and proteins were then transferred to a 
polyvinylidene difluoride membrane (Hybond-P, Amersham). Mouse monoclonal 
antibodies to STAT1, phosphorylated STAT1 (Tyr-701) (both Zymed) or STAT2 (BD 
Transduction Laboratories), a rabbit polyclonal antibody to phosphorylated STAT2 
(Upstate Biotechnology), a goat polyclonal antibody to IFNAR1 (Abcam), and a 
rabbit polyclonal to IFNAR2 (PBL Biomedical Laboratories) were used as primary 
antibodies. Detection was performed using the relevant horseradish peroxidase 
conjugated secondary antibodies (Jackson Immunochemicals) and enhanced 
chemiluminescence reagents (ECL+, Amersham). 
 
FACS analysis. K562 and K562.∆ CprME-PAC2A (1 x 10
6 per reaction) were stained 
with anti-IFNAR2 antibody in RPMI containing 2% FBS at 4°C. Detection was 
performed using a phycoerythrin-conjugated donkey anti-rabbit secondary antibody  10
(Jackson Immunochemicals) and samples analysed on a Becton Dickinson FACScan. 
Data anaylsis was performed using WinMDI software. 
 
Dengue virus infection of K562 cells. K562 cells were incubated with dengue virus 
type 2 (New Guinea C strain) at a multiplicity of infection of 4 and then grown in 
RPMI containing 10% FBS. After 48 hours, cells were air-dried onto glass slides and 
fixed in cold methanol:acetone (50:50 v/v). Cells were dual-labeled with mouse anti- 
dengue NS1 antibody (5H5.4) and rabbit anti-STAT2 antibody (C20, Santa Cruz 
Biotechnology). Fluorescein isothiocyanate-conjugated goat anti-rabbit and Texas 
Red-conjugated horse anti-mouse antibodies (both Vector Laboratories) were used for 
detection. Images were analysed on a BioRad Radiance 2100 confocal microscope. In 
parallel experiments, cells (2 x 10
6 per reaction) were lysed and analysed by 
immunoblotting as described above. 
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RESULTS 
Dengue replicon RNA replication is resistant to IFN-α .  Previous studies have 
shown that the antiviral effect of IFN-α  on dengue virus infection in cell culture is 
markedly abrogated if treatment is delayed by a few hours after infection (5, 6), 
suggesting that dengue virus can counter the IFN response once replication has been 
established. We tested directly whether IFN could inhibit established dengue RNA 
replication in the form of the dengue virus replicon ∆ CprME-PAC2A, which is stably 
maintained in K562.∆ CprME-PAC2A cells (manuscript in preparation). 
K562.∆ CprME-PAC2A cells were grown in the presence of 0, 10, 100, 1000 or 10000 
IU/ml IFN-α 2a for 24 hours, and dengue replicon RNA levels were measured by 
quantitative RT-PCR. In addition, the effect of 100 IU/ml IFN-α  on levels of cell-
associated and secreted NS1 protein were analysed by Western blotting and ELISA, 
respectively. Figure 2 shows that IFN-α  had no significant effect on dengue replicon 
RNA levels or NS1 expression. These data confirm previous evidence suggesting that 
established dengue RNA replication is resistant to IFN-α . (5). 
 
Antiviral action of IFN-α  is blocked by dengue RNA replication. We next tested 
whether the presence of dengue replicons inhibits the general antiviral action of IFN 
in cells. K562 cells that did and did not contain replicons were first treated with IFN-
α 2a and then infected with an IFN-sensitive virus, EMCV. The basis of this technique 
is that inhibition of the antiviral action of IFN by dengue replicons results in rescue of 
EMCV replication, which is detected in a modified plaque assay on A549 cells. 
Figure 3 shows that, in the absence of IFN-α 2a, EMCV replication was equal in cells 
that did and did not contain replicons. As expected, pre-treatment of K562 cells with  12
either 10 or 100 IU/ml IFN-α 2a dramatically inhibited replication of EMCV. In 
contrast, pre-treatment of K562.∆ CprME-PAC2A cells with the same concentrations 
of IFN-α 2a had no effect on EMCV replication (Fig. 3). In order to prove that dengue 
RNA replication inhibited the IFN response, the EMCV rescue assay was repeated 
using K562.∆ CprME-PAC2A cells that had previously been “cured” of the replicon 
by continuous growth in the presence of glycyrrhizic.acid. “Cured” K562 cells were 
negative for the presence of dengue NS1 protein and dengue RNA by indirect 
immunofluorescence and RT-PCR, respectively (manuscript in preparation). “Cured” 
K562 cells reverted to the IFN-responsive phenotype of the original K562 cells (data 
not shown). Taken together, these data show that the antiviral activity of IFN is 
blocked in the presence of dengue replicons. 
 
IFN-α -induced gene expression is inhibited in replicon-containing cells. Different 
viruses have evolved a diverse range of molecular mechanisms that act on different 
cellular targets to inhibit IFN-mediated antiviral pathways (9, 13). In order to test 
whether the observed inhibition of the antiviral effect of IFN in replicon-containing 
cells was due at least in part to inhibition of IFN signal transduction, we first 
measured induction of MxA and PKR gene transcription. These genes are classical 
ISGs that contain an ISRE within the promoter region (20) and encode proteins that 
are key mediators of the antiviral effects of IFN (13). K562 cells that did and did not 
contain replicon were stimulated with IFN-α 2a for 6 and 24 hours, and MxA and 
PKR gene transcription were analysed by quantitative RT-PCR. As expected, IFN 
induced transcription of both of these genes in K562 cells. In contrast, IFN induction 
of MxA and PKR gene transcription was dramatically inhibited in K562.∆ CprME-
PAC2A cells (Fig. 4). Having shown that induction of two genes, MxA and PKR, is  13
inhibited in replicon-containing cells, we examined the global pattern of IFN-
inducible gene transcription in cells that did and did not contain replicons using a 
custom macroarray. We found that the IFN response was profoundly suppressed in 
K562.∆ CprME-PAC2A cells when compared with K562 cells. Table 1 lists the ISGs 
that were most up-regulated (more than 4-fold) in K562 cells in response to IFN, and 
shows the comparative data from K562.∆ CprME-PAC2A cells. These data indicate 
that IFN-α -induced gene expression is inhibited in cells containing dengue replicons, 
although not absolutely, and suggest that IFN-α  signal transduction is inhibited. 
 
Dengue RNA replication inhibits early events in IFN-α  signaling by down-
regulating steady-state STAT2 levels. In order to determine whether early events in 
IFN signal transduction were inhibited in replicon-containing cells, we performed 
Western blot analysis of STAT1 phosphorylation in K562 cells that did and did not 
contain replicons. Steady-state levels of STAT1 were similar in each cell line (Fig. 
5A). As expected, treatment with IFN-α  induced STAT1 phosphorylation in K562 
cells. Levels of phosphorylated STAT1 (STAT1-P) were significantly lower in 
K562.∆ CprME-PAC2A cells in response to IFN-α , but the response was restored to 
normal in “cured” K562 cells. In contrast, STAT1-P levels were not reduced in 
K562.∆ CprME-PAC2A cells in response to IFN-γ , which signals through a distinct 
but overlapping pathway (9); in fact, we observed a consistent increase in STAT1 
phosphorylation in response to IFN-γ  in K562.∆ CprME-PAC2A cells when compared 
with K562 cells (Fig. 5A). In order to ensure that these observations were not limited 
to the specific cell type used, these experiments were repeated using THP-1 cells that 
stably expressed ∆ CprME-PAC2A, with similar results (Fig. 5B). These data imply  14
that early components of the IFN-α  but not IFN-γ  signal transduction pathway are 
targets for dengue virus inhibition. 
 
We next performed Western blot analysis of STAT2 phosphorylation, which is a key 
step in IFN-α  but not IFN-γ  signaling (9). Figures 5A and B show that steady-state 
levels of STAT2 were  very markedly reduced in both K562 and THP-1 cells 
containing dengue replicons when compared with parental cells. Levels of STAT2-P 
in response to IFN-α  were also greatly reduced in both replicon-containing cell lines. 
“Cured” K562 cells reverted to the phenotype of parental K562 cells, with similar 
steady-state levels of STAT2, and STAT2-P in response to IFN-α  (fig. 5A). In order 
to confirm that cells containing dengue replicons did not have generally reduced 
expression of proteins involved in the first part of the IFN-α  signal transduction 
pathway, we examined levels of IFNAR1 and IFNAR2. Total IFNAR1 and IFNAR2 
protein levels were assessed by Western blotting and were similar in K562 and 
K562.∆ CprME-PAC2A cells (Fig. 6A). Cell surface expression of IFNAR2 was 
measured by flow cytometry and was similar in K562 cells that did and did not 
contain replicons (Fig. 6B); reagents to examine cell surface expression of IFNAR1 
by FACS analysis were not available. Similar levels of IFNAR1 and IFNAR2 were 
also found in THP-1 cells that did and did not contain replicons (data not shown). 
Taken together, these data show that the presence of dengue replicons specifically 
inhibits early events in IFN-α  but not IFN-γ  signal transduction by reducing STAT2 
levels.  
 
Dengue virus infection reduces STAT2 levels.  In order to determine whether 
STAT2 expression is also reduced in dengue-infected cells, we infected K562 cells  15
with dengue virus type 2 and analysed STAT2 expression in individual cells using 
dual-label immunofluorescence. We observed infected cells with markedly reduced 
staining for STAT2 compared with neighboring, uninfected cells (fig. 7A and B).  In 
order to assess STAT2 expression in the whole population of cells infected with 
dengue virus, we analysed STAT2 levels 48 hours post-infection by immunoblotting. 
At this time point, approximately 30-50% of cells that had been infected stained 
strongly positive for NS1 protein by immunofluorescence. Figure 7C shows that 
STAT2 levels were markedly reduced in cells infected with dengue virus when 
compared with mock-infected cells, whereas STAT1 levels were unchanged. 
Collectively, the data suggest that down-regulation of STAT2 expression is a key 
component of dengue virus countermeasures against the human IFN response.  16
DISCUSSION 
In this study, we used human cell lines that stably express dengue replicons to show 
that dengue RNA replication inhibits early events in IFN signaling. This work extends 
a related study published by Muñoz-Jordan and colleagues during the progress of our 
research, showing that dengue virus proteins NS2A, NS4A and NS4B have the 
capacity to inhibit nuclear translocation of STAT1-P in response to IFN-β  (25). We 
show here for the first time that dengue RNA replication not only reduces STAT1-P 
levels in response to IFN-α , but also results in marked reduction of STAT2-P levels 
as a consequence of reduced steady-state levels of STAT2. We first made this 
observation in dengue replicon-containing cells, and subsequently in cells infected 
with dengue virus. Since STAT2-P recruits STAT1 for phosphorylation in response to 
IFN-α  (22), generating STAT1/STAT2 heterodimers, all our data can be explained if 
dengue virus specifically down-regulates STAT2 levels in order to counter the IFN 
response. In keeping with this, dengue RNA replication did not reduce STAT1 
phosphorylation in response to IFN-γ , which is independent of STAT2 (22). In fact, 
dengue replicon RNA replication increased rather than decreased STAT1 
phosphorylation in response to IFN-γ , consistent with previous data showing 
increased STAT1 phosphorylation (30) and IFN-γ -mediated gene transcription (1) in 
the context of reduced STAT2 levels. The mechanism underlying this effect and its 
biological significance are, as yet, unknown. 
 
We conclude that dengue virus specifically inhibits IFN-α /β  signaling by down-
regulating expression of STAT2. Muñoz-Jordan and colleagues reported conflicting 
data showing inhibition of both IFN-α /β  and IFN-γ -mediated STAT1 phosphorylation 
by dengue NS4B, and dengue virus infection, in LLCMK2 (monkey kidney) cells,  17
and suggested that common players involved in both signaling pathways (which does 
not include STAT2) were likely targets for IFN antagonism by dengue (25). The 
differences in our findings may reflect interspecies differences in IFN antagonism. 
Although the cell tropism of dengue virus in humans is not definitively known, the 
predominant targets are probably cells of hematopoietic origin, in particular dendritic 
cells, monocytes and macrophages, and also hepatocytes (2, 40, 41). In this study, we 
used human cell lines (K562 and THP-1) related to cells targeted by dengue in vivo, 
and our data provide the basis for further work to confirm the relevance of our 
observations in human dengue infection. 
 
Despite the fact that IFN-α  signaling was not completely blocked in dengue replicon-
containing cells, supra-physiological concentrations of IFN-α 2a had no significant 
effect on dengue replicon RNA replication or protein production. It is possible that 
dengue utilizes more than one mechanism to counter the IFN response, as has been 
suggested for other viruses including another flavivirus, hepatitis C virus (8, 28, 37, 
38). Alternatively, inhibition of IFN signaling by reducing STAT2 levels may be 
sufficient for dengue replication to proceed faster than can be inhibited by the reduced 
IFN antiviral response. Future work will elucidate whether STAT2 levels are reduced 
as a consequence of down-regulation of STAT2 gene transcription or protein 
synthesis, or enhanced degradation of STAT2 protein. Further data are also needed to 
know if the capacity to reduce STAT2 levels is conserved among all dengue strains 
(including field isolates) and in any members of the Flaviviridae family other than 
dengue. Recent data suggest that Japanese Encephalitis Virus also inhibits IFN-α  
signal transduction but utilizes a different mechanism that results in reduced levels of 
phosphorylated Tyk2 (and hence STAT2-P) without altering expression of STAT2  18
(23). Two important human pathogens in the Paramyxoviridae family of enveloped, 
negative-strand RNA viruses, Respiratory Syncytial Virus and Human Parainfluenzae 
Virus Type 2, have been shown to subvert IFN antiviral responses by reducing 
STAT2 levels (26, 30). This effect is likely mediated through proteosome-mediated 
degradation of STAT2. However, other paramyxoviruses do not reduce steady-state 
STAT2 levels and instead have evolved a variety of different strategies to block IFN-
α /β  signaling (10, 19, 32, 43), which is a broadly effective strategy to counter the IFN 
response. 
 
Future work is needed to define the precise interaction between components of the 
IFN signal transduction pathway and specific dengue proteins. Replicon-containing 
human cell lines are powerful tools for these studies because preliminary evidence 
suggests that several dengue non-structural proteins may act together to produce 
strong, species-specific inhibition of IFN (25). We were concerned to ensure that our 
observations did not reflect selection of an IFN-defective sub-population of cells 
during generation of our stable replicon-containing cell lines. Several lines of 
evidence mitigate against this conclusion and suggest that our results accurately 
reflect an important host-pathogen interaction that subverts the IFN response: 
replicon-expressing cells were propagated from a total population of transfected cells 
rather than individual cell clones; our observations were the same in two cell types, 
K562 and THP-1; and K562 cells that had previously expressed replicons and had 
been “cured” with glycyrrhizic acid reverted to the phenotype of parental K562 cells. 
Most importantly, the key observation made in our replicon model, namely reduction 
in STAT2 levels, led us to the same finding in cells infected with dengue virus. 
Collectively, the data suggest that down-regulation of STAT2 expression is an  19
important mechanism by which dengue virus subverts innate antiviral defences 
mediated by IFN. 
 
Understanding the molecular basis of the race between dengue virus replication and 
the IFN response early in infection would represent a critical advance: the efficiency 
with which dengue virus evades the IFN response in humans is probably an important 
factor in early viral replication and hence disease pathogenesis. Further data will 
elucidate whether differences in IFN antagonism contribute to differences in 
pathogenicity observed between dengue strains (31). Understanding the molecular 
mechanisms that dengue virus utilizes to subvert innate immune responses mediated 
by IFN may also inform strategies for rational attenuation, in order to generate safer 
and more cost-effective dengue vaccine candidates. 
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FIGURE LEGENDS 
 
Figure 1. Schematic showing construction of plasmid pDEN∆ CprME-PAC2A. 
(A)  Dengue virus type 2 cDNA infectious clone (in plasmid pDVWS601 (29)), 
showing single open reading frame encoding 3 structural genes (C, core; prM, pre-
membrane; E, envelope), 7 non-structural (NS) genes and flanking 5’- and 3’-
untranslated regions (UTR). (B) pDEN∆ CprME: a large in-frame deletion has been 
introduced within the region encoding structural genes. (C) pDEN∆ CprME-PAC2A: 
an antibiotic selection cassette encoding puromycin N-acetyl transferase (PAC) and 
foot-and-mouth disease virus protein 2A has been cloned in place of the deleted 
structural genes. 
 
Figure 2. Dengue replicon RNA replication is resistant to IFN-α . (A) 
K562.∆ CprME-PAC2A cells were grown in the presence of various concentrations 
IFN-α 2a as indicated for 24 hours. Dengue replicon RNA levels were measured using 
quantitative PCR and normalised to GAPDH mRNA. (B)  K562.∆ CprME-PAC2A 
cells were grown in the presence of 100 IU/ml IFN-α 2a for 0, 6 and 24 hours. Cell 
lysates (2 x 10
5 cells per reaction) were separated by SDS-PAGE, and then dengue 
NS1 protein was analysed by immunoblotting. K562 cells were included as a negative 
control. (C) K562.∆ CprME-PAC2A cells were grown in the absence (black bars) or 
presence (white bars) of 100 IU/ml IFN-α 2a for 24 and 48 hours. The cumulative 
concentrations of NS1 in the culture supernatants at each time-point were measured 
by ELISA. 
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Figure 3. Antiviral effect of IFN-α  is blocked in dengue replicon-containing cells. 
K562 cells (solid lines) and K562.∆ CprME-PAC2A cells (broken lines) were treated 
with 0 (z), 10 () or 100 ({) IU/ml IFN-α 2a for 24 hours. Cells were then infected 
with EMCV, and after a further 24 hours supernatants were harvested and serially 
diluted on confluent A549 cells. After 24 hours, A549 cells were fixed and stained 
with methyl violet. The amount of staining was quantified by measuring the optical 
density (OD) of each well at 570 nm. More EMCV replication results in increased cell 
death and hence lower OD readings. 
 
Figure 4. Induction of classical ISGs by IFN-α  is inhibited in dengue replicon-
containing cells. K562 cells (black bars) and K562.∆ CprME-PAC2A cells (white 
bars) were stimulated with 100 IU/ml IFN-α 2a for 6 and 24 hours. (A) MxA and (B) 
PKR gene transcription were measured by real-time PCR and normalised to the 
housekeeping gene GAPDH. 
 
Figure 5. Dengue RNA replication inhibits STAT1 and STAT2 phosphorylation 
in response to IFN-α  and reduces steady-state levels of STAT2. (A) K562, K562. 
∆ CprME-PAC2A and “cured” K562 cells, or (B)  THP-1 and THP-1.∆ CprME-
PAC2A cells were treated with and without 100 IU/ml IFN-α  or IFN-γ  for 30 min., 
and then lysed in SDS loading buffer. Proteins were separated by SDS-PAGE and 
then analysed by immunoblotting using specific antibodies for phosphorylated 
STAT1, STAT1, phosphorylated STAT2 and STAT2 as indicated. 
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Figure 6. Dengue RNA replication does not affect IFNAR protein levels. (A) Cell 
lysates from K562 and K562.∆ CprME-PAC2A cells were separated by SDS-PAGE 
and then analysed by imunoblotting using specific antibodies for IFNAR1 and 
IFNAR2 as indicated. (B)  K562 and K562.∆ CprME-PAC2A were stained with 
specific anti-IFNAR2 antibodies and analysed by flow cytometry. Cells stained with 
secondary antibody alone (gray-filled plot) were included as a negative staining 
control. 
 
Figure 7. Dengue virus infection reduces STAT2 levels. K562 cells were infected 
with dengue virus for 48 hours and then dual-stained with (A) anti-dengue NS1 
mouse monoclonal antibody followed by Texas Red-labeled secondary antibody to 
detect dengue-infected cells, and (B) anti-STAT2 rabbit polyclonal antibody followed 
by fluorescein-labeled secondary antibody to detect STAT2. Cells were visualised by 
confocal microscopy. The arrow shows an infected cell. (C) Cell lysates were 
separated by SDS-PAGE and then analysed by immunoblotting using specific 
antibodies for dengue NS1, STAT1 and STAT2 as indicated. Mock-infected cells 
were included for comparison. 
  
 Table 1. ISG transcription in response to IFN-α  in cells that do and do not 
contain dengue replicons. ISGs up-regulated more than 4-fold in K562 cells are 
shown in comparison to K562.∆ CprME-PAC2A cells. 
   Fold  induction 
    K562   K562.∆ CprME-
PAC2A 
IFN-alpha induced protein 27  55.8  11.5 
 
VCAM-1 30.6  2.6 
 
MxA 17.9  1.8 
 
IFN-alpha induced protein (clone IFI-616)  12.9  1.1 
 
met proto-oncogene (hepatocyte growth factor)  7.9  1.8 
 
PSMB9 7.9  0.4 
 
IFN-induced protein 17  7.5  1.3 
 
Vipirin (cig5)  7.2  1.3 
 
IL-15 6.5  1.1 
 
9-27mrna 6.4  1.2 
 
STAT1 6.2  1.1 
 
STAT4 6.2  1.5 
 
IFIT1 6.1  1.3 
 
KIAA0284 5.6  1.5 
 
STAT1 (91kDa)  4.9  1.8 
 
IFN induced transmemberane protein 3  4.9  1.4 
 
INDO 4.8  0.6 
 
IL-6 4.8  0.6 
 
IFN induced transmemberane protein 2  4.5  1.1 
 
MAP2K4 4.5  1.0 
 
IFI35 4.4  1.1 
 
Homo sapiens STAT  4.1  1.6 
 